Trna-seq service (msr-seq)
Transfer RNAs and their derived small RNAs are among the most abundant nucleic acid molecules in the cell—tRNAs and related small RNAs make up over 90% of RNA copy numbers in a human cell—yet they remain dramatically underexplored relative to mRNA and miRNA. The barrier has been technical: tRNAs are notoriously difficult to reverse transcribe due to their structure and dense modifications, so standard small RNA-seq systematically misses them. MSR-seq solves this. It captures full-length tRNAs and their fragments in a single workflow while preserving the modification signatures (such as m1A m22G, and PseudoU) that govern tRNA function and processing, opening a high-abundance regulatory layer that has been effectively invisible to conventional methods. This layer matters because it carries real biological and clinical signal. These molecules are implicated in cell proliferation, RNA silencing, and translational regulation, sitting at the control point of protein synthesis and stress response
MesoRNA delivers this readout as a turnkey service. We handle library prep, sequencing, and bioinformatics, returning quantified abundance of full-length tRNAs, their fragments, and base-level modification signatures in a single dataset—no separate assays or specialized in-house expertise required. We accept tissue, cultured cells, and plasma/serum inputs, supporting both discovery research and biomarker work, and we offer custom bioinformatics for project-specific questions. Reach out for a quote, turnaround, and sample prep guidance.
About MesoRNA
MesoRNA specializes in advanced sequencing technologies for small non-coding RNAs, known as mesoRNAs, which range from 30 to 300 nucleotides. The company has developed its proprietary MSR-seq technology to enable comprehensive, multiplexed next-generation sequencing (NGS) library preparation. This platform allows researchers to measure tens of thousands of unique molecules per sample with high base-calling accuracy. Additionally, the company provides a full-service laboratory option for sample processing and is developing a TL-qPCR assay intended to translate biomarker discoveries into diagnostic applications. By addressing the technical challenges historically associated with studying these pervasive but under-researched molecules, MesoRNA aims to complete the understanding of the central dogma of molecular biology.
These tools serve academic laboratories, core facilities, and diagnostic developers who require precise, scalable methods to analyze the biological roles of mesoRNAs. By streamlining the workflow from library preparation to bioinformatics analysis, the company helps users overcome previous limitations in small RNA research. MesoRNA, founded in 2023 and based in Chicago, grew out of over a decade of academic research led by Dr. Tao Pan. The company provides a crucial resource for institutions seeking to investigate the regulatory functions of non-coding RNAs, which constitute a significant majority of human cellular nucleic acids, potentially unlocking new pathways for biological discovery and diagnostic development.
delivered to your inbox.